small lung, target phase II
ovarian, proceed phase III
breast, start phase II
EC0531 targets a chemotherapy drug to folate receptors over expressed on cancer cells. EC0531 targets a “super-potent” chemotherapy drug called tubulysin using our second-generation guidance system.
EC0531 is currently in preclinical development.
EC1069 targets a chemotherapy drug to PSMA receptors expressed on prostate cancer cells. EC1069 is constructed with a proprietary, high affinity targeting ligand that binds to PSMA together with a potent chemotherapy drug that inhibits microtubule activity.
EC1069 is currently in preclinical development.
EC0746 targets a highly potent anti-folate drug to activated macrophages overexpressing folate receptors.
EC0746 is currently in preclinical development.
EC0565 targets an immunosuppressive drug to folate receptors that are over-expressed on activated macrophages present within sites of inflammation. The drug is a very potent inhibitor of mTOR.
EC0565 is currently in preclinical development.
EC0371 is a folate-targeted, water soluble form of rapamycin that selectively inhibits mTOR activity in polycystic kidneys to reduce abnormal growth.
EC0371 is currently in preclinical development.
About 3 other Vintafolide threatments not sure yet, might be:
- 2 other ones
Seen Merck's expiration in patents, might be in hurry, would not be surprised they make kind of a deal early wiht Tubulysin
And of course, Endocyte will market EC 20 and other imaging diagnostics, ...!